NCT03607487View on ClinicalTrials.gov

A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

August 13, 2019

Study Completion Date

August 13, 2019

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

INCB054707

INCB054707 tablet administered orally once daily at the protocol-defined dose.

DRUG

Placebo

Placebo tablet administered orally once daily.

Trial Locations (13)

4000

Investigative Site, Roskilde

8200

Investigative Site, Aarhus

23538

Investigative Site, Lübeck

44791

Investigative Site, Bochum

R3M 3Z4

Investigative Site, Winnipeg

E3B 1G9

Investigative Site, Fredericton

L4M 7G1

Investigative Site, Barrie

N6H 5L5

Investigative Site, London

L3P 1X2

Investigative Site 009, Markham

L4C 9M7

Investigative Site 008, Richmond Hill

N8W 5L7

Investigative Site 007, Windsor

J2B 5L4

Investigative Site, Drummondville

J7Z 7E2

Investigative Site, Saint-Jérôme

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY